This HTML5 document contains 79 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n18https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n16http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n8http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/
dbpedia-jahttp://ja.dbpedia.org/resource/

Statements

Subject Item
dbr:Prostaglandin_DP2_receptor
dbo:wikiPageWikiLink
dbr:Fevipiprant
Subject Item
dbr:Fevipiprant
rdf:type
wikidata:Q8386 dbo:ChemicalSubstance n16:ChemicalObject dbo:Drug owl:Thing
rdfs:label
フェビピプラント Fevipiprant
rdfs:comment
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). As of 2016, it is in phase III clinical trials for the treatment of asthma. フェビピプラント（Fevipiprant）は、CRTH2受容体に対してアンタゴニストとなる化合物の1種である。ただし、2016年現在、医薬品としては実用化されていない。
foaf:depiction
n8:Fevipiprant.svg
dcterms:subject
dbc:Benzosulfones dbc:Antiasthmatic_drugs dbc:Trifluoromethyl_compounds dbc:Carboxylic_acids dbc:Receptor_antagonists
dbo:wikiPageID
51257095
dbo:wikiPageRevisionID
1033019669
dbo:wikiPageWikiLink
dbc:Antiasthmatic_drugs dbc:Benzosulfones dbr:Clinical_trial dbr:Phases_of_clinical_research dbr:Receptor_antagonist dbr:Pharmaceutical_drug dbr:International_Nonproprietary_Name dbr:Asthma dbr:Setipiprant dbr:Prostaglandin_DP2_receptor dbc:Carboxylic_acids dbc:Receptor_antagonists dbc:Trifluoromethyl_compounds dbr:Novartis dbr:Glucuronidation
owl:sameAs
dbpedia-ja:フェビピプラント wikidata:Q27077292 yago-res:Fevipiprant n18:2Xs5d
dbp:wikiPageUsesTemplate
dbt:Respiratory-system-drug-stub dbt:Asthma_and_copd_rx dbt:Reflist dbt:Prostanoidergics dbt:Drugbox dbt:As_of
dbo:thumbnail
n8:Fevipiprant.svg?width=300
dbp:atcPrefix
none
dbp:bioavailability
Unaffected by food
dbp:c
19
dbp:casNumber
872365
dbp:chemspiderid
23582412
dbp:eliminationHalfLife
72000.0
dbp:excretion
Renal
dbp:f
3
dbp:h
17
dbp:iupacName
{2-methyl-1-[4--2-benzyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}acetic acid
dbp:kegg
D10631
dbp:legalStatus
Investigational
dbp:metabolism
Hepatic glucuronidation
dbp:n
2
dbp:o
4
dbp:pubchem
23582412
dbp:routesOfAdministration
Oral
dbp:s
1
dbp:smiles
CC1=CCCO
dbp:stdinchi
1
dbp:stdinchikey
GFPPXZDRVCSVNR-UHFFFAOYSA-N
dbp:unii
2
dbo:abstract
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). As of 2016, it is in phase III clinical trials for the treatment of asthma. On Monday, December 16, 2019, Switzerland-based Novartis officially announced that it was jettisoning fevipiprant from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. The firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug. フェビピプラント（Fevipiprant）は、CRTH2受容体に対してアンタゴニストとなる化合物の1種である。ただし、2016年現在、医薬品としては実用化されていない。
prov:wasDerivedFrom
wikipedia-en:Fevipiprant?oldid=1033019669&ns=0
dbo:wikiPageLength
4517
dbo:casNumber
872365-14-5
dbo:fdaUniiCode
2PEX5N7DQ4
dbo:kegg
D10631
dbo:pubchem
23582412
foaf:isPrimaryTopicOf
wikipedia-en:Fevipiprant
Subject Item
dbr:Setipiprant
dbo:wikiPageWikiLink
dbr:Fevipiprant
Subject Item
dbr:QAW039
dbo:wikiPageWikiLink
dbr:Fevipiprant
dbo:wikiPageRedirects
dbr:Fevipiprant
Subject Item
wikipedia-en:Fevipiprant
foaf:primaryTopic
dbr:Fevipiprant